Biotech companies at BPI 2026

49 biotech companies are at BPI 2026 — 71 presentations on the program. Most represented: Ultragenyx (3 on the program), Genetix Biotherapeutics (2 on the program), Third Arc Bio (2 on the program). 16 of them have their own page in this guide.

All 346 organizations at BPI 2026 →

Showing 1–13 of 49 organizations

Organization	BPI 2026 Attendance
Ultragenyx Novato, California	1 Associate Director · 1 SVP, Global CMC Development · 1 MSAT Executive Director
ultragenyx.com Biotech Develops and commercializes therapies for rare and ultra-rare genetic diseases, including AAV gene therapies.	Talk Thu Sep 24 12:00pm–12:30pm Cell Bank Characterization and Qualification Strategy for AAV PCLs Gene Therapy Manufacturing & Analytics Talk Thu Sep 24 4:30pm–5:30pm Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development Development of Emerging Cell & Gene Therapies · with Mill Creek Consulting, Astellas Institute for Regenerative Medicine, Genetix Biotherapeutics Panel Fri Sep 25 9:00am–10:00am Keynote Panel Discussion: Navigating BLA Success - Strategies for Streamlined Gene Therapy Approval Success Gene Therapy Manufacturing & Analytics · with University College Cork, GenSight Biologics, Rocket Pharmaceuticals +1 more
GB Genetix Biotherapeutics Somerville, Massachusetts	1 Senior Director, Process Development · 1 VP of CMC Strategy & Ops
Biotech Gene therapy company, formerly bluebird bio, with marketed lentiviral gene therapies for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy.	Chair Thu Sep 24 9:20am–9:30am Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics Cell Therapy Manufacturing & Analytics Talk Thu Sep 24 11:45am–12:30pm Designing for the Unknown: How Do You Plan CGT Manufacturing Facilities When the Patient Count is a Moving Target? Development of Emerging Cell & Gene Therapies · with Hart Companies, Bristol Myers Squibb, Chrysalis Talk Thu Sep 24 4:30pm–5:30pm Panel Discussion: Starting with the End in Mind: Designing Smart and Phase Appropriate Manufacturing for Successful Cell and Gene Therapy Development Development of Emerging Cell & Gene Therapies · with Mill Creek Consulting, Ultragenyx, Astellas Institute for Regenerative Medicine Talk Fri Sep 25 12:40pm–1:20pm PANEL: Women in Bioprocessing: Leadership, Innovation, and Career Growth in Biotech Innovation and Community Stage (Exhibit Hall) · with Association for Women in Science, Massachusetts Chapter, Third Arc Bio, Lyric Bio +1 more
TA Third Arc Bio	1 Senior Vice President · 1 Director, CMC & Analytical Development
Biotech Develops multifunctional antibody therapeutics, including bispecific T cell engagers.	Talk Wed Sep 23 2:30pm–3:00pm CMC challenges associated with highly potent and difficult-to-manufacture bispecific antibodies CMC Strategy & Manufacturing Performance Talk Fri Sep 25 12:40pm–1:20pm PANEL: Women in Bioprocessing: Leadership, Innovation, and Career Growth in Biotech Innovation and Community Stage (Exhibit Hall) · with Association for Women in Science, Massachusetts Chapter, Genetix Biotherapeutics, Lyric Bio +1 more Talk Fri Sep 25 3:00pm–3:30pm PANEL DISCUSSION: Strategies to Future-Proof Manufacturing Processes for Large-Scale Production CMC Strategy & Manufacturing Performance · with ClearB Therapeutics, University College Cork, Gyros Protein Technologies +1 more
AskBio Research Triangle Park, North Carolina	1 Associate Director, Process Development · 1 Senior Scientist
askbio.com Biotech Gene therapy developer, a Bayer subsidiary, working on AAV-based treatments.	Talk Thu Sep 24 10:00am–10:30am Building an AAV Production Strategy Utilizing Stable Producer Cell Lines for Scalable, Gene Therapy Manufacturing Gene Therapy Manufacturing & Analytics Talk Thu Sep 24 2:45pm–3:15pm Effective Tech Transfer of Manufacturing Processes to CDMO Partners Gene Therapy Manufacturing & Analytics
Prime Medicine Cambridge, Massachusetts	1 Director of Automation & Assays · 1 Analytical Development Scientist II
primemedicine.com Biotech Biotechnology company developing gene editing therapies based on prime editing, delivered with technologies such as RNA-lipid nanoparticles.	Talk Wed Sep 23 1:00pm–1:45pm From Bench to BLA: Automation and AI-Accelerated Potency Assay Validation Scientific Lunch Presentation 7 Digital Biomanufacturing & AICell & Gene Therapy Talk Thu Sep 24 2:45pm–3:15pm Leveraging Platform-Based, Multi-Attribute LC Assays to Characterize Multi-components Prime Editing (PE) RNA-LNP Development of Emerging Cell & Gene Therapies
Rocket Pharmaceuticals Cranbury, New Jersey	1 Director, Technical Operations · 1 CMC Project Manager
rocketpharma.com Biotech Develops lentiviral and AAV gene therapies for rare childhood disorders.	Panel Fri Sep 25 9:00am–10:00am Keynote Panel Discussion: Navigating BLA Success - Strategies for Streamlined Gene Therapy Approval Success Gene Therapy Manufacturing & Analytics · with University College Cork, Ultragenyx, GenSight Biologics +1 more Talk Fri Sep 25 12:40pm–1:20pm PANEL: Women in Bioprocessing: Leadership, Innovation, and Career Growth in Biotech Innovation and Community Stage (Exhibit Hall) · with Association for Women in Science, Massachusetts Chapter, Genetix Biotherapeutics, Third Arc Bio +1 more
SB Siren Biotechnology San Francisco, California	1 SVP, Vector Development · 1 Director of Translational Research
Biotech Develops AAV-based immuno-gene therapies for cancer, including high grade gliomas.	Talk Fri Sep 25 10:00am–10:30am From Vial to Brain: Demonstrating AAV Gene Therapy Stability During Convection-Enhanced Delivery Gene Therapy Manufacturing & Analytics Talk Fri Sep 25 11:55am–12:15pm The Siren Experience: Advancing SRN-101 for High Grade Gliomas Development of Emerging Cell & Gene Therapies
Solid Biosciences Charlestown, Massachusetts	1 VP, Manufacturing · 1 Scientist II
solidbio.com Biotech Develops gene therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy.	Keynote Thu Sep 24 9:00am–10:00am Keynote Panel Discussion: Strategies for Scaling Up, Accelerating and Commercializing Gene Therapy Manufacturing Gene Therapy Manufacturing & Analytics · with University College Cork, Sangamo Therapeutics, Gokyo Biosciences +2 more Talk Fri Sep 25 11:45am–12:15pm Machine Learning and Mechanistic Modeling Approaches Within Upstream Process Development to Improve AAV Product Quality Gene Therapy Manufacturing & Analytics
NB NurExone Biologic	1 RD Director · 1 CEO
Biotech Biotechnology company developing exosome-based regenerative therapies and drug delivery, initially for spinal cord and nerve injury.	Talk Fri Sep 25 2:00pm–2:30pm Unlocking the Regenerative Potential of Exosomes: From Bioprocess Development to Advanced Drug Delivery Platform CMC Strategy & Manufacturing Performance
Opthea Melbourne, Australia	1 Senior Director of CMC Technical Operations
opthea.com Biotech Biopharmaceutical company developing biologic therapies for retinal diseases.	Talk Tue Sep 22 1:00pm–2:00pm Analytical & Quality Symposia 4: BPI School CMC & Manufacturing Strategy Panel Tue Sep 22 3:00pm–3:45pm BPI School Round Up Symposia 4: BPI School · with Disc Medicine, North Carolina State University, Körber Pharma Chair Wed Sep 23 8:55am–9:00am Chairperson's Opening Remarks CMC Strategy & Manufacturing Performance Chair Wed Sep 23 1:55pm–2:00pm Chairperson Remarks CMC Strategy & Manufacturing Performance
Aspen Neuroscience San Diego, California	1 VP, Process & Analytical Development
aspenneuroscience.com Biotech Develops autologous iPSC-derived neuron replacement therapy for Parkinson's disease.	Talk Wed Sep 23 5:00pm–5:45pm CGT Exhibit Hall Roundtable Discussions CGT Community Hub (Exhibit Hall) · with GenSight Biologics Panel Fri Sep 25 9:00am–10:00am Panel Discussion: Decentralized Manufacturing in Cell Therapy: Overcoming Implementation Challenges and Enhancing Patient-Centric Solutions Cell Therapy Manufacturing & Analytics · with Tigen Pharma, Massachusetts General Hospital, Advanced Regenerative Manufacturing Institute (ARMI)
CT ClearB Therapeutics	1 Chief Technology Officer
Biotech Drug developer working on therapies for chronic hepatitis B.	Talk Fri Sep 25 2:00pm–2:30pm Navigating regulatory complexities in external manufacturing CDMO Partnering & External Manufacturing Talk Fri Sep 25 3:00pm–3:30pm PANEL DISCUSSION: Strategies to Future-Proof Manufacturing Processes for Large-Scale Production CMC Strategy & Manufacturing Performance · with University College Cork, Third Arc Bio, Gyros Protein Technologies +1 more
Disc Medicine Watertown, Massachusetts	1 Director, Cell Line and Upstream Process Development, Disc Medicine.
discmedicine.com Biotech Clinical-stage developer of therapies for serious hematologic diseases.	Talk Tue Sep 22 9:00am–9:45am Introduction To Upstream Manufacturing Symposia 4: BPI School Upstream & Cell Culture Panel Tue Sep 22 3:00pm–3:45pm BPI School Round Up Symposia 4: BPI School · with North Carolina State University, Körber Pharma, Opthea